Edited by Peter Hillerberg2 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The week's biggest scheduled event is already underway. UNH and JNJ both hold Q3 calls this morning, each carrying market caps above $300 billion. BAC follows Wednesday at 6:45am ET. Banks dominate the rest of the week, with PGR, SCHW, and BNY all due before Friday. Nordic names join the calendar too. reports Q3 on Thursday.
MDT's MiniMed share exchange offer has been oversubscribed today. The company is moving to exchange 252.8 million remaining shares at a ratio of 4.5939 MiniMed shares per Medtronic ordinary share. This corporate action explains the sharp jump in Medtronic's short interest, which leapt from 1.6% to 10.1% of free float in one week. Large-cap spin mechanics, not pure bear conviction, appear to be driving the move.
MRNA is the biggest flow story in the MSCI November review. ORTEX Index Rebalance Radar puts an 81% probability on Moderna re-entering MSCI North America. The ranking cut-off falls on 19 October. If confirmed on 11 November, forced buying of $3.3B is pencilled in. That is equal to less than one day of normal volume, making the one-day trade impact severe. Charter Communications faces the opposite pressure, with a 65% deletion forecast and $693M of potential selling.
Zalando sits 7.2% below the MSCI World exit line with a 51% deletion probability and $343M of forced selling at stake. Flutter Entertainment is 8.1% below its own line. The 19 October cut-off leaves little time for either to recover. Finnish telco Elisa carries a 35% deletion probability at $250M of potential selling.
Keefe, Bruyette and Woods maintained its Underperform rating on Allstate today and cut the price target to $232. That adds to a broadly cautious tone across US utilities, where analysts trimmed targets on five major names Monday. ORTEX alt data shows an Xcel Energy reactor recorded output 10.0 standard deviations below its own history on 11 October.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
